Skip to main content
. Author manuscript; available in PMC: 2010 Aug 27.
Published in final edited form as: Biochemistry. 2009 Jun 16;48(23):5187–5198. doi: 10.1021/bi802067u

Figure 2.

Figure 2

Modifications on BRAF lead inhibitor HB591. (a) Chemical structures of lead inhibitor HB591, precursor NP580, and CS292. (b) Dose–response curves of HB591, NP580, and CS292 from an ELISA-based BRAF kinase inhibition assay. (c) Chemical structure and dose– response curve of the pyridocarbazle compound CNSE176 without the ruthenium complex portion. The data represent an average of triplicate measurements.